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OBJECTIVES: To compare medication treatment pat-
terns for patients who initiated on olanzapine (OLZ)
versus risperidone (RIS).
METHODS: Retrospective analysis of a large, geographi-
cally diverse claims database of insured individuals 
identiﬁed 670 enrollees who: (1) were diagnosed with
schizophrenia; (2) initiated on OLZ (n = 423) or RIS (n
= 247) monotherapy, and (3) had no use of OLZ or RIS
in one year prior-initiation. Multivariate analyses were
used to compare the OLZ and RIS groups with respect
to treatment duration and likelihood of receiving 
medication for at least 80% of days during the one-year
post-initiation, likelihood of switching between study
drugs, and likelihood of receiving concomitant treatment
for Parkinsonian symptoms. Regressions controlled for
demographics, comorbidities, and previous medication
use patterns.
RESULTS: Compared to RIS (mean dose = 3.32mg/day),
patients treated with OLZ (mean dose = 10.45mg/day)
experienced a 29.4% increase in treatment duration (162
days vs. 213 days; p < 0.0001), a higher probability of
receiving medication for at least 80% of days (Odds Ratio
= 2.057, p = 0.0002), a decrease in the probability of 
concomitant use of anti-Parkinsonian medications (Odds
Ratio = 0.639; p = 0.0284). Patients who initiated on
OLZ were less likely to switch to RIS than vice versa
(Odds Ratio = 0.275; p < 0.0001).
CONCLUSIONS: Compared to RIS, patients treated
with OLZ experienced a longer duration of therapy, an
increased likelihood of receiving 80% of days of therapy,
a decreased likelihood of concomitant use of anti-
Parkinsonian agents, and a lower probability of switch-
ing among medications of interest.
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Studies have shown that systemic absorption of oph-
thalmic beta-blockers (OBBs) can potentially cause severe
systemic side effects.
OBJECTIVES: To evaluate the use of OBBs among
patients with a contraindication or precaution against its
use.
METHODS: We conducted a retrospective analysis of
pharmacy and medical claims data from a West Coast
health plan. Patients receiving a prescription for oph-
thalmic betaxolol, carteolol, levobunolol, metipranolol,
or timolol between 7/1/98 and 6/30/00 were included in
this study. Study cohorts were identiﬁed based upon the
ﬁrst OBB agent received and were followed for 180 days.
Patients receiving prescriptions for different OBBs that
were more than 180 days apart were categorized as
having two episodes of care. OBBs are contraindicated 
in patients with sinus bradycardia/persistent severe 
bradycardia, asthma, COPD, and greater than ﬁrst degree
heart block. OBBs have precautions against use in 
patients having diabetes mellitus, congestive heart 
failure, Raynaud’s phenomenon, or using oral beta-
blockers. OBB use was deﬁned as inappropriate if used
simultaneously with oral beta-blockers, within 15 days of
heart block diagnosis, or within 6 months of the other 
conditions.
RESULTS: A total of 9,094 unique patients contributed
9,294 episodes of care. The percentage of patients with a
contraindication or precaution against OBB use, respec-
tively, was 12.7% and 20.9% (betaxolol: 19.9% with
contraindication, 22.7% with precaution; carteolol:
9.7%, 20.9%; levobunolol: 13.0%, 21.5%; metipra-
nolol: 9.2%, 21.5%; timolol: 10.7%, 20.3%). Overall,
29.6% of patients had at least one contraindication or
precaution against OBB use, and 7.6% had multiple 
contraindications and/or precautions.
CONCLUSION: Nearly three out of ten patients who
received an OBB had a contraindication or precaution
against its use. Further research is needed to determine
the incidence of clinically signiﬁcant adverse effects from
prescribing OBBs in these patient populations, and to
identify alternative glaucoma medications that may be
more appropriate for these patients.
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OBJECTIVES: Current treatments for non-melanoma
skin cancer (NMSC) can be problematic when lesions are
in cosmetically sensitive sites. Patients may also be unsuit-
able for standard therapies for other reasons. Cosmetic
procedures are therefore common. Methyl aminolevuli-
nate (Metvix) photodynamic therapy (MAL PDT) has
comparable lesion response rates and superior cosmetic
outcomes in such patients. The aim of this study was to
estimate the mean total costs of treatment to the UK
